Mendus
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. They leverage their expertise in dendritic cell biology to develop advanced immunotherapies that are effective and safe.
Industries
biotechnology
health-care
wellness
Nr. of Employees
small (1-50)
Products
Clinical-stage allogeneic dendritic cell-based immunotherapy candidates
Cell-based immunotherapy candidates developed from dendritic cell biology intended as maintenance therapies to reduce tumor recurrence and improve long-term outcomes; currently in clinical development including late-stage trial preparations.
Clinical-stage allogeneic dendritic cell-based immunotherapy candidates
Cell-based immunotherapy candidates developed from dendritic cell biology intended as maintenance therapies to reduce tumor recurrence and improve long-term outcomes; currently in clinical development including late-stage trial preparations.
Services
Collaborative research and clinical development partnerships
Collaborative R&D and clinical development partnerships to advance cell-based immunotherapy candidates from preclinical research into clinical trials.
Collaborative research and clinical development partnerships
Collaborative R&D and clinical development partnerships to advance cell-based immunotherapy candidates from preclinical research into clinical trials.
Expertise Areas
- Cancer immunotherapy development
- Dendritic cell-based therapy
- Clinical trial management for oncology
- Immune monitoring and biomarker-driven development
Key Technologies
- Dendritic cell-based immunotherapy
- Allogeneic (off-the-shelf) cell therapy
- Immune monitoring and biomarker assays
- Translational immunology